Efficacy of a novel anti-IL-1B receptor modulator in reducing preterm birth impact on neurovascular health - Year two
Preterm neonates ill-adapted to the extra uterine environment are prone to increased inflammation in multiple organs and the proinflammatory interleukine IL-1b has been closely implicated in brain injury associated with preterm birth (PTB). Notably, PTB survivors have a greater propensity to develop ischemic brain lesions long after birth. Here, we hypothesize that the neural vasculature of premature infants becomes irresponsive to hypoxic-ischemic stress. Our project will study the molecular mechanisms underlying brain revascularisation potential in a mouse model of PTB combining in utero inflammation and neonatal metabolic stress. We will evaluate the efficacy of newly discovered selective anti-IL-1 receptor modulator (Rytvela, Rytvel Biotech) in preserving brain vascular function. By targeting IL-1b signalling, the inhibition of neonatal inflammation could thus protect children from enhanced vulnerability to brain damage and its devastating consequences on health.